OR WAIT null SECS
The new Abzena facility will initially include four modular suites with up to two 2000-L bioreactors, followed by the addition of two more 2000 L suites.
Abzena, a US-based global partner research organization, announced on April 15, 2021 that it has chosen Sanford, NC, as the location for its new good manufacturing practices (GMP) facility.
The new facility, which will be designed specifically for phase III and commercial manufacturing of biologics, will initially include four modular suites with up to two 2000-L bioreactors, followed by the addition of two more 2000 L suites, Abzena said in a company press release. The facility will also handle continuous manufacturing and perfusion, with manufacturing beginning in 2022.
“We are delighted to announce the investment of our newest site in Sanford, NC,” said Jonathan Goldman, MD, CEO of Abzena, in the press release. “Our goal is to support our partners and the patients they serve with this expansion in [C]GMP [current good manufacturing practice] biologics manufacturing services. We are pleased to provide integrated asset development with a full suite of in-house services from discovery through clinical and commercial phases without the need for technology transfer. We are very pleased to be welcomed by North Carolina.”